The clinical failure rate of first-line antibiotic treatment is the key cost driver in community-acquired lower respiratory tract infections

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 278-279

  Van Barlingen, H J J ^a   Volmer, T ^b   Lacey, Larry F ^c  

^a Lewin Group   (Netherlands)

^b Glaxo Wellcome GmbH and Co   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; TREATMENT FAILURE;

EID: 0032725440     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00091     Document Type: Conference Paper

References (4)

1. Gladen HE. Computer modelling antibiotic therapy costs. Impact of therapeutic range. Drugs 1988; 35 Suppl. 2: 208-13
2. Backhouse RJ, Kapasi M, Noble I, et al. Modelling the use of three antibiotics in the management of community acquired pneumonia. Br J Med Econ 1995; 8: 195-210
3. Backhouse R, Shakespeare A, Hutton J. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis. Br J Med Econ 1995; 8: 11-25
4. Wool C, Cerutti R, Garbagna N, et al. A cost-effective study of four different antibiotics in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Br J Med Econ 1996; 10: 159-68